December 3 - 4 2026 | Encore Boston Harbor, US
From Rhetoric... To Results.
The Regulatory Mandates, Value Dossier Strategy, and Sex-Specific Clinical Data Scaling Driving Market Access.
The Women's Health Infrastructure Report 2026
Help us uncover how healthcare leaders are funding, delivering, reimbursing and scaling women's health across the United States.
✅ 5 Questions • ✅ 60 Seconds • ✅ Published September 2026
For Pharma & Life Sciences
Accelerate market access, de-risk value dossiers, and align your clinical trial frameworks with tightening federal diversity mandates.
The paradigm for modern U.S. biopharma has fundamentally shifted.
Tightened federal guidelines now mandate absolute sex-specific data diversity in clinical cohorts—while navigating the commercial pipeline from molecular discovery to regional health plan formulary adoption remains an expensive hurdle. Women’s HealthX 2026 serves as the definitive cross-functional clearinghouse built to solve this friction.
Connect your RWE, HEOR, and clinical development teams directly with the regional managed care directors, policy makers, and health system procurement committees controlling the ultimate commercial checkbooks. Isolate the exact evidence-generation criteria required to defend your portfolios, clear utilization gates, and accelerate launch velocity.
The Regulatory Catalyst: Navigating Federal Compliance
Strengthening Clinical Trial Integrity Through Regulatory Science.
Biopharma organizations cannot afford lagging compliance infrastructure. Shifting federal mandates now directly impact investigational new drug protocols, real-world data collection, and post-market tracking timelines. Evaluate the immediate regulatory milestones, evidence priorities, and sex-specific cohort diversity enforcement strategies directly with Dr. Kaveeta Vasisht (Associate Commissioner for Women’s Health, FDA) on our main stage.
The Next Generation of Clinical Trial Execution
Optimizing Cohort Recruitment, RWE Synthesis, and Launch Velocity.
Building a defensible clinical data pipeline is a complex commercial hurdle. Benchmark your trial protocols directly against the advanced decentralized methodologies, patient preference metrics, and health economic models used by elite life sciences leaders. Isolate the exact evidence synthesis pathways required to secure rapid regional adoption and maximize clinical confidence.
De-Risk Your Portfolios Against Managed Care Barriers
Aligning Value Dossiers with Underwriting & Formulary Gates.
Commercial scale depends entirely on passing institutional insurance gating. Gain unvarnished, direct visibility into the exact cost-containment metrics, risk adjustment models, and economic criteria utilized by health plan medical directors. Benchmark your market-access value dossiers directly alongside executive leadership from Cigna, Humana, CVS Health, and Elevance to ensure your therapeutics survive utilization management reviews.
Organizations you'll meet at WoHX
Explore the Program
Evidence, Data & Innovation
Sexual Health & Wellness
Lead The Next Era Of Women's Healthcare
